- .
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.. and informal settlements. "this is far from the best start in life"..
- .
"we were quite surprised to find there were no significant differences," says study author.
.daily pilot.